The HDHD3 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population targeting the HDHD3 gene within the Homo sapiens HEK293T cell background. This heterogeneous cell pool carries targeted disruptions in the HDHD3 locus, enabling loss-of-function studies while curtailing clonal selection artifacts. Designed for mitochondrial RNA processing and nucleotide metabolism research, this product offers a robust and versatile model for uncovering the biological contributions of HDHD3.
HEK293T cells are a human embryonic kidney epithelial derivative that constitutively expresses the SV40 large T antigen, a feature that promotes episomal amplification of plasmids bearing the SV40 origin and drives high-level transient protein production. Their adherent growth properties, diploid karyotype, and well-annotated transcriptome make them a preferred host for functional genomics. Critically, HEK293T cells maintain active mitochondrial RNA degradation pathways involving PNPT1 and SUV3, furnishing a physiologically relevant milieu for HDHD3 investigation.
HDHD3 belongs to the haloacid dehalogenase superfamily and is postulated to function as a phosphatase that directly interacts with polynucleotide phosphorylase (PNPT1). PNPT1, operating in concert with the RNA helicase SUV3, constitutes the primary mitochondrial exoribonuclease complex responsible for transcript turnover and RNA surveillance. HDHD3 may modulate PNPT1 catalytic activity or substrate binding, thereby affecting downstream mitochondrial RNA stability and nucleotide metabolic flux. Thus, HDHD3 serves as a putative regulator of the PNPT1-SUV3 axis, and its ablation is anticipated to disrupt mitochondrial gene expression coordination.
Within the HEK293T context, HDHD3 knockout provides an isogenic system to dissect mitochondrial RNA dynamics without tissue-specific confounders. The cell line endogenously expresses the critical interacting partner PNPT1 and the helicase SUV3, enabling direct observation of HDHD3-dependent phenotypes. Disruption of HDHD3 is expected to perturb mitochondrial transcript processing and nucleotide pools, potentially modeling features of mitochondrial dysfunction observed in poorly characterized disorders. This system thus bridges fundamental biochemical characterization and disease-relevant mechanistic inquiry.
Researchers can deploy this polyclonal knockout in an array of downstream applications. Co-immunoprecipitation assays coupled with western blotting validate HDHD3-PNPT1 complex formation, while RNA-seq and targeted RT-qPCR quantify mitochondrial transcript alterations. Enzyme activity assays assess PNPT1 function, and immunofluorescence microscopy visualizes changes in mitochondrial morphology or PNPT1 localization. These integrated approaches facilitate comprehensive dissection of HDHD3??s role in RNA metabolism. For further information or custom requests, please reach out to Ascent Research.
